← FDA DRUG APPROVALS

FDA NDA · NDA205645

TIGECYCLINE

Sponsor: FRESENIUS KABI USA

APPLICATION
NDA205645
TYPE
NDA
ORIGINAL APPROVAL
2016-12-01
LATEST ACTION
2025-03-31
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Discontinued

Products

TIGECYCLINE · ReferenceDiscontinued
TIGECYCLINE 50MG/VIAL · POWDER · INTRAVENOUS

Approval history

2025-03-31Labeling · Supplement 13 · standard — Label ↗AP
2020-11-16Labeling · Supplement 4 · standard — Label ↗AP
2019-04-04Labeling · Supplement 3 · standard — Letter ↗AP
2017-08-15Labeling · Supplement 1 · standard — Label ↗AP
2016-12-01Type 5 - New Formulation or New Manufacturer · Original · standard — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →